Futura Medical Cleared to Launch Eroxon Intense in EEA and UK

Key Facts

In a move reflecting the expansion of small-cap healthcare firms into major markets, Futura Medical has announced regulatory clearance for the launch of Eroxon Intense. According to reports, the erectile dysfunction gel has been cleared for distribution across the European Economic Area and the United Kingdom. This milestone follows the completion of design, validation, and pre-market regulatory work under existing CE and UKCA certifications.

This expansion builds on the company's flagship franchise, with the new product designed to deliver a faster and stronger sensorial effect than the current version. Home-user tests yielded positive results, with a majority of participants recording satisfactory experiences and successful intercourse. These clearances now enable commercial partner Cooper Consumer Health to launch the formulation across its licensed territories.

Operationally, the company is now looking toward the US market, where it expects FDA clearance during the second half of 2026.